8 results on '"Motoji Murase"'
Search Results
2. Safety analysis of zolpidem in elderly subjects 80 years of age or older: adverse event monitoring in Japanese subjects
- Author
-
Kazuko Nakagawa, Seisuke Hirota, Tadao Ishizuka, Masato Yamamura, Ayami Kajiwara, Haruo Koda, Kazunori Morita, Kentaro Oniki, Motoji Murase, and Junji Saruwatari
- Subjects
Male ,Aging ,Zolpidem ,Pediatrics ,medicine.medical_specialty ,Drug-Related Side Effects and Adverse Reactions ,Pyridines ,medicine.drug_class ,Poison control ,Occupational safety and health ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Injury prevention ,Insomnia ,Humans ,Hypnotics and Sedatives ,Medicine ,030212 general & internal medicine ,Medical prescription ,Adverse effect ,Aged, 80 and over ,business.industry ,musculoskeletal, neural, and ocular physiology ,medicine.disease ,Psychiatry and Mental health ,Sedative ,Female ,Medical emergency ,Drug Monitoring ,Geriatrics and Gerontology ,Pshychiatric Mental Health ,medicine.symptom ,business ,Gerontology ,psychological phenomena and processes ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Prescriptions of non-benzodiazepine sedative hypnotics, e.g. zolpidem, for insomnia in elderly subjects 80 years of age or older have markedly increased in the USA. However, a meta-analysis of the risks and benefits of hypnotics in older people reported the benefits associated with hypnotics use are outweighed by the risks. This study aimed to investigate the safety of zolpidem administration in extremely old elderly.The prevalence of adverse reactions to zolpidem was investigated in a subpopulation of participants in the Drug Event Monitoring project of the Japan Pharmaceutical Association. A total of 1011 (316 males and 695 females) zolpidem users, including 261 (25.8%) subjects 80 years of age or older without cognitive or mental complications, were eligible for the analysis.The elderly and female patients were prescribed significantly lower doses of zolpidem than their counterparts. Adverse symptoms after the last prescription were reported by 60 (5.9%) subjects. The most common symptoms were impaired balance and/or falls (1.8%) and morning drowsiness (1.3%). The multiple logistic regression analyses showed that subjects 80 years of age or older were at lower risk of adverse symptoms (odds ratio 0.39, 95% confidence intervals: 0.17-0.88).Our findings in a real-world clinical setting suggest that low-dose zolpidem can be safely prescribed to subjects 80 years of age or older without cognitive or mental complications.
- Published
- 2015
3. Risk Factors for Adverse Symptoms During Dipeptidyl Peptidase-IV Inhibitor Therapy: A Questionnaire-Based Study Carried Out by the Japan Pharmaceutical Association Drug Event Monitoring Project in Kumamoto Prefecture
- Author
-
Seisuke Hirota, Tadao Ishizuka, Motoji Murase, Masato Yamamura, Kazuko Nakagawa, Haruo Koda, Junji Saruwatari, Kentaro Oniki, Ayami Kajiwara, Kazunori Morita, Ayana Kita, and Misaki Sakata
- Subjects
Male ,Drug ,Societies, Pharmaceutical ,medicine.medical_specialty ,Alcohol Drinking ,media_common.quotation_subject ,Pharmacology ,Hypoglycemia ,Toxicology ,Dipeptidyl peptidase ,law.invention ,Sex Factors ,Japan ,Randomized controlled trial ,Risk Factors ,law ,Surveys and Questionnaires ,Internal medicine ,Adverse Drug Reaction Reporting Systems ,Humans ,Hypoglycemic Agents ,Medicine ,Pharmacology (medical) ,Aged ,media_common ,Dipeptidyl-Peptidase IV Inhibitors ,business.industry ,Liver Diseases ,Incidence (epidemiology) ,Medical record ,medicine.disease ,Clinical trial ,Sitagliptin ,Drug Therapy, Combination ,Female ,business ,medicine.drug - Abstract
Meta-analyses of randomized clinical trials have reported that dipeptidyl peptidase IV (DPP-4) inhibitors are well tolerated and that the incidence of hypoglycemia with the use of DPP-4 inhibitors is similar to that observed with placebos. However, in general, provider-oriented methods using medical record reviews offer lower rates of non-serious, symptomatic adverse drug reactions (ADRs) than patient-oriented methods. Moreover, severe hypoglycemia occurred in three clinical trials using sitagliptin, but in two of these trials this phenomenon has been previously described only in the drug application data in the US.The aim of this study was to assess the profile of patient-reported symptomatic ADRs under DPP-4 inhibitor therapy and to detect risk factors for hypoglycemic and non-hypoglycemic adverse symptoms in daily clinical practice.We analyzed a subpopulation of participants in the Drug Event Monitoring (DEM) project of the Japan Pharmaceutical Association. An anonymous survey was conducted in February 2012 to assess the self-perception of adverse symptoms during a median 28 (4-88) days after the last prescription of DPP-4 inhibitors by means of interviews of pharmacists using structured questionnaires.A total of 864 males and 686 females were included. The prescribed DPP-4 inhibitors included sitagliptin (75.4 %), alogliptin (15.5 %), vildagliptin (8.8 %) and linagliptin (0.3 %). Mild hypoglycemic symptoms were reported by 34 individuals (2.2 %) receiving monotherapy of sitagliptin (10/402) or alogliptin (3/65), or combination therapy of sitagliptin (15/767) or alogliptin (6/176) with other hypoglycemic agents. In the multiple regression model, hypoglycemic symptoms were found to be significantly associated with liver disease, female sex and alcohol consumption more than three times per week. Non-hypoglycemic symptoms were reported by 57 individuals (3.7 %), the most common symptoms of which were gastrointestinal symptoms (2.1 %). Combination therapy was only found to be associated with nonhypoglycemic symptoms.The present study suggested that hypoglycemic symptoms under therapy with sitagliptin or alogliptin may be associated with liver disease, female sex and alcohol consumption, all of which are potentially capable of leading to poor gluconeogenesis because they decrease the counter-regulatory hormonal responses to hypoglycemia.
- Published
- 2013
4. Higher risk of sulfonylurea-associated hypoglycemic symptoms in women with type 2 diabetes mellitus
- Author
-
Tadao Ishizuka, Kentaro Oniki, Ayana Kita, Haruo Koda, Seisuke Hirota, Masato Yamamura, Junji Saruwatari, Motoji Murase, Kazuko Nakagawa, Ayami Kajiwara, and Kazunori Morita
- Subjects
Male ,medicine.medical_specialty ,Hypoglycemia ,Japan ,Risk Factors ,Diabetes mellitus ,Internal medicine ,medicine ,Humans ,Hypoglycemic Agents ,Pharmacology (medical) ,Aged ,Aged, 80 and over ,business.industry ,Incidence (epidemiology) ,Incidence ,Type 2 Diabetes Mellitus ,General Medicine ,Odds ratio ,Middle Aged ,medicine.disease ,Repaglinide ,Concomitant drug ,Glimepiride ,Endocrinology ,Sulfonylurea Compounds ,Diabetes Mellitus, Type 2 ,Female ,business ,medicine.drug - Abstract
Although some evidence suggests that women may be at greater risk for hypoglycemia, no conclusion has been reached, and female sex has not been taken into account in antidiabetic drug-induced hypoglycemia. This study aimed to determine whether females are at a higher risk of sulfonylurea (SU)-associated hypoglycemia in daily clinical practice. The incidence of adverse reactions of SU was investigated in 2119 Japanese patients who participated in the Drug Event Monitoring project of the Japan Pharmaceutical Association, which was conducted in Kumamoto prefecture. A multiple logistic regression analysis was used to determine the association between the incidence of hypoglycemic symptoms and female sex, with adjusted odds ratios (ORs) and 95 % confidence intervals (95 % CIs). Female sex was found to be significantly associated with hypoglycemic symptoms (female vs. male; OR 2.04; 95 % CI 1.22–3.41; p = 0.007). The concomitant use of other antihyperglycemic agents (≥2 vs. 0 concomitant drug; OR 2.80; 95 % CI 1.17–6.67; p = 0.021), a shorter duration of diabetes medication (
- Published
- 2015
5. Absence of gargling affects topical adverse symptoms caused by inhaled corticosteroids in females
- Author
-
Tadao Ishizuka, Kentaro Oniki, Ayana Kita, Junji Saruwatari, Masato Yamamura, Haruo Koda, Ayami Kajiwara, Seisuke Hirota, Kazuko Nakagawa, Kazunori Morita, and Motoji Murase
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,Male ,Inhaled corticosteroids ,Young Adult ,Adrenal Cortex Hormones ,Risk Factors ,Administration, Inhalation ,medicine ,Immunology and Allergy ,Gargling ,Humans ,Anti-Asthmatic Agents ,Mouth mucosa ,Adverse effect ,Asthma ,Aged ,Aged, 80 and over ,Stomatitis ,Hoarseness ,Inhalation ,business.industry ,Mouth Mucosa ,Middle Aged ,medicine.disease ,Oral Hygiene ,Dry-powder inhaler ,Anesthesia ,Pediatrics, Perinatology and Child Health ,Female ,business - Abstract
Topical adverse events caused by inhaled corticosteroids (ICS) are suspected to be more common in females. Although gargling or mouth washing after inhalation is recommended as the gold standard for preventing adverse events due to ICS, the preventive effects of this method have not been confirmed in real-world studies. This study aimed to examine the association between gargling or mouth washing and the incidence of topical adverse symptoms in males and females in daily practice.We analyzed a subpopulation of participants in the Drug Event Monitoring (DEM) project of the Japan Pharmaceutical Association. An anonymous survey was performed in February 2010, to assess the self-perception of topical adverse symptoms during ICS use by conducting interviews of pharmacists using structured questionnaires.A total of 412 males and 480 females were included. The patients used a dry-powder inhaler (DPI) (71.2%), pressurized meter-dose inhaler (pMDI) with (7.5%) or without (16.6%) a spacer or inhalation solution (4.7%) as the delivery device. Topical adverse symptoms occurring after previous prescriptions were reported by 41 (4.6%) subjects. The common symptoms were hoarseness, stomatitis and dry mouth (1.3%, 1.1% and 1.1%, respectively). In the multiple regression model, the presence of symptoms was found to be significantly associated with the absence of gargling or mouth washing after inhalation [adjusted odds ratio (OR): 3.75, 95% confidence interval (95%CI): 1.33-10.59, p = 0.012]. When stratified by gender, the absence of gargling or mouth washing was identified to be a risk factor in females only (OR: 4.32, 95%CI: 1.11-16.87, p = 0.035) and not in males (OR: 3.26, 95%CI: 0.65-16.33, p = 0.151). Furthermore, the association between the absence of gargling or mouth washing and the incidence of topical adverse symptoms was significant in the patients using DPI (OR: 4.85, 95%CI: 1.66-14.14, p = 0.004), but not in those using the other devices.In this study, the absence of gargling or mouth washing after ICS use was associated with topical adverse symptoms, especially in females. To achieve good adherence to treatment and improve the quality of life, female patients with asthma should strictly practice the gargling or mouth washing method.
- Published
- 2013
6. Reaction of aromatic N-oxides with dipolarophiles. X. Role of charge-transfer complexes in 1,3-dipolar cycloaddition of pyridine N-oxides to phenyl isocyanate
- Author
-
Kazunobu Harano, Takuzo Hisano, Rie Kondo, Toshikazu Matsuoka, and Motoji Murase
- Subjects
Pyridine-N-oxide ,General Chemistry ,General Medicine ,Photochemistry ,Charge-transfer complex ,Cycloaddition ,chemistry.chemical_compound ,Reaction rate constant ,chemistry ,Drug Discovery ,Pyridine ,Polymer chemistry ,1,3-Dipolar cycloaddition ,Solvent effects ,Equilibrium constant - Abstract
In the 1, 3-dipolar cycloaddition reaction of 3-methylpyridine N-oxide with phenyl isocyanate, spectroscopic evidence indicates that phenyl isocyanate forms charge-transfer complexes with both pyridine N-oxide and aromatic solvents such as pyridine. In connection with the charge-transfer complex formation, the solvent effect on the site selectivity was investigated. The most prominent solvent effect was observed in the reaction using 3-methylpyridine as a solvent. The equilibrium constants for the interaction of 3-methylpyridine N-oxide with phenyl isocyanate in several solvents were found to be quite large, indicating that the reaction mixtures favor complex formation. The proton nuclear magnetic resonance (1H-NMR) spectra of the mixtures show a high field shift of the methyl signal of 3-methylpyridine N-oxide due to charge-transfer complexation. Based on these results, the structure and role of the complexes are discussed.
- Published
- 1986
7. ChemInform Abstract: Pericyclic Reactions of Pyridine N-Oxides
- Author
-
Ryuichi Fukuoka, Kazunobu Harano, Toshikazu Matsuoka, Motoji Murase, Hirotoshi Yamada, and Takuzo Hisano
- Subjects
chemistry.chemical_compound ,Pericyclic reaction ,Organic reaction ,Chemistry ,Pyridine ,Organic chemistry ,General Medicine - Published
- 1985
8. Pericyclic Reactions of Pyridine N-Oxides
- Author
-
Takuzo Hisano, Kazunobu Harano, Toshikazu Matsuoka, Ryuichi Fukuoka, Motoji Murase, and Hirotoshi Yamada
- Subjects
Pharmacology ,Organic Chemistry ,Analytical Chemistry - Published
- 1985
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.